Second and subsequent lines of systemic therapy in endometrial cancer – a real-life clinical experience
Authors:
MUDr. Bednaříková Markéta, Ph.D. 1,2; MUDr. Koblížková Michaela 2; Mgr. Ovesná Petra, Ph.D. 2,3; MUDr. Hausnerová Jitka, Ph.D. 4; MUDr. Ehrlichová Lucie 1,2; MUDr. Felsinger Michal, Ph.D. 2; Ing. Tomková Martina 2; doc. MUDr. Minář Luboš, Ph.D. 2; doc. MUDr. Weinberger Vít, Ph.D. 2
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Klinika gynekologie, porodnictví a neonatologie LF MU a FN Brno
2; Institut biostatistiky a analýz, LF MU, Brno
3; Ústav patologie, LF MU a FN Brno
4
Published in:
Klin Onkol 2026; 39(3): 184-194
Category:
Original Articles
doi:
https://doi.org/10.48095/ccko2026184
Overview
Background: Patients with advanced or recurrent endometrial cancer who progress after platinum-based chemotherapy face a poor prognosis, and treatment options have historically been limited. The introduction of immunotherapy, alone or in combination with targeted agents, has substantially expanded therapeutic options in subsequent treatment lines. This study evaluated the efficacy and clinical benefit of second - and subsequent-lines of systemic therapy in a real-life cohort of patients with advanced or recurrent endometrial cancer. Methods: This retrospective, single-center analysis included patients treated at University Hospital Brno who were considered for second-line systemic therapy after failure of platinum-based chemotherapy between 2013 and 2024. Clinicopathological and molecular characteristics, systemic treatment modalities, best overall response, time to progression, and disease-specific survival were assessed. Results: A total of 43 patients were identified; second-line treatment was initiated in 41 patients (95.3%). Of these, 26 (63.4%) received second-line chemotherapy, 14 (34.1%) received pembrolizumab alone or in combination with lenvatinib, and one patient (2.4%) received hormonal therapy. The median disease-specific survival for the entire cohort was 13.4 months (95% confidence interval 8.5–27.2 months). Among patients with re-administration of platinum-based chemotherapy, the median disease-specific survival was 27.2 months. Patients receiving pembrolizumab ± lenvatinib had a median survival of 23.4 months, whereas those treated with non-platinum chemotherapy had a median survival of 6.7 months. Two patients without active second-line treatment had a median disease-specific survival of 2.7 months. Nearly half of the patients treated with pembrolizumab ± lenvatinib experienced a prolonged time to progression compared with those receiving primary platinum-based chemotherapy. Conclusions: In patients with advanced or recurrent endometrial cancer after platinum failure, active systemic therapy may prolong survival and improve disease control. The greatest clinical benefit was observed with pembrolizumab alone or in combination with lenvatinib. An individualized, sequential approach to palliative systemic therapy is crucial to maximize clinical benefits.
Keywords:
endometrial cancer – immunotherapy – Chemotherapy – systemic treatment – pembrolizumab – second and subsequent lines of therapy – lenvatinib
Sources
1. Krejčí D, Mužík J, Šnábl I et al. Portál epidemiologie novotvarů v ČR. [online]. Dostupné z: https: //www.svod.cz/.
2. Linkos. Zhoubný novotvar těla děložního (C54).[online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/32-16-zhoubny-novotvar-tela-delozniho-c54/.
3. Concin N, Matias-Guiu X, Cibula D et al. ESGO-ESTRO--ESP Guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol 2025; 26 (8): e423–e435. doi: 10.1016/S1470-2045 (25) 00167-6.
4. van Wijk FH, Aapro MS, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group. Ann Oncol 2003; 14 (3): 441–448. doi: 10.1093/annonc/mdg112.
5. Miller DS, Filiaci VL, Mannel RS et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/gog0209). J Clin Oncol 2020; 38 (33): 3841–3850. doi: 10.1200/JCO.20.01076.
6. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33 (17): 1974–1982. doi: 10.1200/JCO.2014.59.4358.
7. Mirza MR, Chase DM, Slomovitz BM et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023; 388 (23): 2145–2158. doi: 10.1056/NEJMoa2216334.
8. Powell MA, Bjørge L, Willmott L et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol 2024; 35 (8): 728–738. doi: 10.1016/j.annonc.2024.05.546.
9. Eskander RN, Sill MW, Beffa L et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023; 388 (23): 2159–2170. doi: 10.1056/NEJMoa2302312.
10. van Weelden WJ, Birkendahl PB, Lalisang RI et al. The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis. BJOG 2023; 130 (2): 143–152. doi: 10.1111/1471-0528.17331.
11. Makker V, Taylor MH, Aghajanian C et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38 (26): 2981–2992. doi: 10.1200/JCO.19.02627.
12. O‘Malley DM, Bariani GM, Cassier PA et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022; 40 (7): 752–761. doi: 10.1200/JCO.21.01874.
13. Oaknin A, Gilbert L, Tinker AV et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from garnet-a phase i, single-arm study. J Immunother Cancer 2022; 10 (1): e003777. doi: 10.1136/jitc-2021-003777.
14. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009; 105 (2): 109. doi: 10.1016/j.ijgo.2009.02.010.
15. Bednaříková M, Hausnerová J, Minář L et al. Molecular testing of endometrial carcinoma in real-world clinical practice. Klin Onkol 2023; 36 (3): 215–223. doi: 10.48095/ccko2023215.
16. Eid M, Bednaříková M, Vlažný J et al. Real-world data from a molecular tumor board-assisted cancer care from a single center in the Czech Republic: Is precision oncology an accessible option, or a privilege for a minority of patients? Cancer Med 2025; 14 (15): e71119. doi: 10.1002/cam4.71119.
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228–247. doi: 10.1016/j.ejca.2008.10.026.
18. Krejčí D, Mužík J, Šnábl I et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: https: //www.svod.cz.
19. Noer MC, Antonsen SL, Ottesen B et al. Type i versus type II endometrial cancer: differential impact of comorbidity. Int J Gynecol Cancer 2018; 28 (3): 586–593. doi: 10.1097/IGC.0000000000001184.
20. Cancer Genome Atlas Research Network, Kandoth C, Schultz N et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497 (7447): 67–73. doi: 10.1038/nature12113.
21. Talhouk A, McConechy MK, Leung S et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113 (2): 299–310. doi: 10.1038/bjc.2015.190.
22. Vrede SW, Van Weelden WJ, Bulten J et al. Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer. Gynecol Oncol 2025; 192 : 15–23. doi: 10.1016/j.ygyno.2024.10.028.
23. Kommoss FK, Karnezis AN, Kommoss F et al. L1CAM Further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 2018; 119 (4): 480–486. doi: 10.1038/s41416-018-0187-6.
24. Heffernan K, Nikitas FS, Shukla U et al. Previously treated recurrent or advanced endometrial cancer in england: a real-world observational analysis. Gynecol Oncol 2022; 166 (2): 317–325. doi: 10.1016/j.ygyno.2022.06.011.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2026 Issue 3
Most read in this issue
- Clinical presentations of the most common histiocytic disorders
- Jaký časopis Klinická onkologie chceme?
- Second and subsequent lines of systemic therapy in endometrial cancer – a real-life clinical experience
- 68Ga-DOTATOC PET/CT – a case report of synchronous oncological duplicity with high expression of somatostatin receptors